Sarcopenia News - LARVOL Sigma

Sarcopenia	Welcome, Profile Billing Logout

«1 2...122 123 124 125 126127128 129 130 131 132...401 402 »

|||||||||| Continuous terlipressin infusion improves muscle function but not muscle mass in patients with cirrhosis and portal hypertension (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_2164;
While not statistically significant in this small cohort, the trend towards improvement in SMI and DEXA arm lean mass warrants further investigation with larger and longer studies, given muscle mass tends to take longer to increase than improvements in muscle function. This study provides a promising new therapy for sarcopenia in the sickest cohort of chronic liver disease patients.

|||||||||| TIPS increases muscle mass in patients with decompensated cirrhosis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_2131;
Sarcopenia resolves in a considerable share of patients with cirrhosis after TIPS, which is linked to a clear survival benefit. Patients who do not resolve sarcopenia after TIPS remain at considerable risk of mortality and thus should be timely listed for liver transplantation.

|||||||||| Prehabilitation intervention to maximize early recovery (PRIMER) in liver transplantation: a randomized, controlled trial (Stolz 2) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_2006;
Adherence to physical activity was three-fold higher than reported in recent studies. Home-based prehabilitation is feasible and hold promise for larger trials.

|||||||||| Fat versus lean tissue loss in short term versus long term weight loss: a dynamic effect with implications for NASH trials (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1944;
Non-adipose tissue loss constitutes 37% of the total body weight loss at 1 month while only 20.5 % after 12 months. This could possibly be attributed to more excessive amount of water being lost in early weight loss while the negative energy balance over time will turn into loss of excessive adipose tissue.

|||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Liver Frailty Index is associated with progression-free survival in patients with advanced HCC treated with Atezolizumab/Bevacizumab (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1880;
The Liver Frailty Index is an easy tool for sarcopenia assessment which is associated with PFS in patients with advanced HCC treated with Atezo-Beva. Sarcopenia screening and treatment including nutritional and physical strengthening should be performed for all patients

|||||||||| Transversal psoas muscle thickness measurement is associated with response and survival in patients with hepatocellular carcinoma undergoing immunotherapy (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1863;
Sarcopenia screening and treatment including nutritional and physical strengthening should be performed for all patients Evaluation of sarcopenia using TPMT measurement is reliable and identifies HCC patients with a dismal prognosis and response to immunotherapy.

|||||||||| Potential gut microbial biomarkers for detection of sarcopenia in alcohol-related liver disease patients (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1746;
Aiming Bacteroides to Proteobacteria ratio might be beneficial for the ALD patients having sarcopenia complication which may improve quality of life. Figure: Identified distinctive gut microbiota in S-ALD vs ALD patients.

|||||||||| Long-term outcome following liver transplantation for patients with acute on chronic liver failure grade 3 (ACLF-3): a retrospective matched-controlled study (Lehar 3) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1475;
5- and 10-year patients and graft survivals in ACLF 3 patients were not significantly different from their matched controls with lower ACLF grade or absence of ACLF. 5-year patients

|||||||||| Diagnostic performance of NAFLD fibrosis score in lean NAFLD (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1239;
However, the sensitivity of NFS at the current cut-off value decreased in lean individuals. FIB-4 at the current cut-off value would be a better screening parameter of advanced NAFLD fibrosis in lean individuals.

|||||||||| Impact of visceral adiposity for coronary artery calcification progression in patients with metabolic dysfunction-associated fatty liver disease; multicenter cohort study (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1223;
FIB-4 at the current cut-off value would be a better screening parameter of advanced NAFLD fibrosis in lean individuals. Visceral adiposity is associated with an CAC progression in patients with MAFLD, independent of traditional risk factors.

|||||||||| Sarcopenia is an independent risk factor for non-alcoholic fatty liver disease regardless of fat mass in men: 1:1 propensity score matching analysis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1195;
LSMI was significantly related to NAFLD in men, not in women. This suggests that risk assessment for NAFLD may differ by gender, and such an assessment is particularly warranted for men with low muscle mass regardless of fat mass.

|||||||||| Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non-alcoholic fatty liver disease patients (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1182;
In contrast, HST was not related with MACE. The 5STST could be integrated into the cardiovascular risk stratification of NAFLD patients.

|||||||||| Prevalence and mortality of non-alcoholic fatty liver disease (NAFLD) in non-diabetics, pre-diabetics, and diabetics in the United States (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1174;
2.67 NA 1.76 (0.93 - 3.35) 2.80 (0.91 - 8.60) 1.58 (1.08 - 2.30) Chronic Kidney Diseases NA 1.39 (0.79 - 2.42) 2.68 (2.00 - 3.60) 1.91 (1.22 - 2.98) Sarcopenia NA 1.24 (0.73 - 2.10) 1.53 (1.15 - 2.03) 1.04 (0.72 - 1.48) Aged 20-39 Reference Reference Reference Reference Aged 40-59 16.29 (2.67 - 99.37) 3.21 (1.78 - 5.79) 3.08 (1.39 - 6.82) 4.50 (1.80 - 11.26) Aged 60-74 858.91 (99.05 - 7448.05) 19.33 (9.93 - 37.63) 14.7 (6.62 - 32.66) 16.55 (7.20 - 38.06) Male 7.05 (2.29 - 21.71) 1.62 (1.17 - 2.24) 1.14 (0.83 - 1.55) 1.03 (0.75 - 1.41) Non-Hispanic White 0.38 (0.12 - 1.22) 1.44 (0.91 - 2.28) 1.43 (1.02 - 2.01) 1.96 (1.29 - 2.96) Low income 0.35 (0.07 - 1.69) 1.42 (1.00 - 2.02) 1.28 (0.91 - 1.81) 1.73 (1.22 - 2.45) Active smoker 18.06 (3.78 - 86.36) 2.03 (1.43 - 2.88) 1.55 (1.09 - 2.19) 1.84 (1.08 - 3.13) Models were adjusted for age, sex, race, income, education, smoking, physical activity, healthy eating. Bold p<.05

|||||||||| Sarcopenia at listing for liver transplantation is a negative predictor for post-transplant survival, but not for graft survival (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1089;
To what extent counteracting sarcopenia in this patient population improves post- transplant outcome remains to be elucidated. Figure: Post-transplant survival based on pre-transplant nutritional status

|||||||||| Body composition and MAFLD are associated with prognosis after resection of intrahepatic cholangiocarcinoma (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1065;
This study evidenced a high prevalence of MAFLD in iCCA, suggesting its potential contribution to disease etiology. While being associated with body composition phenotypes regarded as pathological, MAFLD may be associated with improved disease-free survival in patients undergoing surgery for iCCA.

|||||||||| Polycystic disease: a cumbersome benign indication for transplantation (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1063;
In our cohort 16% of pts were pre-transplant colonized by MDR bacteria and post-LT early surgical revisions were needed in 44% of cases. Nevertheless, the expertise of a high-volume transplant Centre allowed to achieve a 3-year survival rate of 94%.

|||||||||| The evolution of the muscle compartment from the listing to six-month post-transplantation: a longitudinal monocentric study (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1061;
Myosteatosis is significantly associated with negative pre-transplant outcomes. After LT, patients improve in muscle strength but not in muscle quantity or quality evaluated by CT-scan.

|||||||||| Altered gut microbiome and stool bile acids in sarcopenia in cirrhosis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1016;
Changes in BAs composition occur in sarcopenic cirrhotic and are linked to compositional changes in the gut microbiome; however, we observed no difference in BAs transforming genes between sarcopenic and non-sarcopenic microbiomes in cirrhosis. Thus, the study demonstrated a potential functional gut microbiome-host interaction linking sarcopenia with the changes in the gut microbiome and stool BAs profiles pointing towards a potential mechanistic interplay in understanding sarcopenia pathogenesis.

|||||||||| Combination of weekly albumin infusion, personalized nutrition and home-based exercise programme improves outcomes of patients with end stage liver disease (Al-Fit study) (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1007;
The combination of weekly albumin infusion, personalized nutritional counselling and monitored home-based physiotherapy is first kind of study in patients with high MELD score more than or equal to 15 to show significant improvement in liver frailty index, reduces MELD score and overall improves quality of life. My study trial enrolement details are as follows - CTRI No : REF/2023/02/063149 Figure :

|||||||||| The gene expression profile of skeletal muscle in end-stage liver disease patients undergoing assessment for liver transplantation with muscle wasting (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_988;
Collectively, these findings highlight distinct signaling pathways which may underscore alterations in skeletal muscle mass and function in ESLD patients. These findings suggest a number of novel therapeutic targets for future interventions which aim to treat sarcopenia.

|||||||||| Role of extracellular vesicles in sarcopenia associated to chronic liver diseases (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_979;
Serum EVs in cirrhotic patients, likely released by damaged liver, could affect skeletal muscle homeostasis and mediate sarcopenic processes by delivering to muscle cells a specific miRNA cargo. Therefore, circulating EVs could be key players of the liver-muscle axis in sarcopenia associated to liver disease.

|||||||||| Serum myostatin decreased after direct acting antivirals for cirrhotic patients (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_763;
Therefore, circulating EVs could be key players of the liver-muscle axis in sarcopenia associated to liver disease. DAA treatment could contribute to improve sarcopenia for LCC patients, possibly by the modulation of sarcopenia-associated molecules.

|||||||||| Clinical interdisciplinary development of a home-based enteral nutrition initiation and refeeding monitoring model of care for patients with chronic liver disease (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_737;
This provided safe and effective EN therapy to a vulnerable group without requiring hospitalisation. The safety, efficacy, acceptability, and cost effectiveness of this model of care compared to traditional inpatient management will be evaluated as part of our feasibility study.

|||||||||| Changes in frailty as a predictor of readmission risk in patients with liver cirrhosis. Preliminary results (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_731;
Although the N of this study does not allow affirmation, the analysis provides crucial evidence to suggest that the delta value of the LFI may be a useful tool to predict the risk of readmission in patients with decompensated cirrhosis. Another added value of these data lies in demonstrating the importance of improving frailty status in this population.

|||||||||| Tyrosol (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_686;
Another added value of these data lies in demonstrating the importance of improving frailty status in this population. In a mouse model of NASH, tyrosol modulates the different populations of immune cells in the liver, counteracting steatosis, fibrosis, oxidative stress and inflammation, all hallmarks of this complex liver disease.

|||||||||| Does sex influence the development of sarcopenia in liver fibrosis? (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_506;
CLD-associated sarcopenia is due to an increase of muscle protein degradation, more evident in females, whereas muscle protein synthesis is not affected by liver fibrosis in both sexes. Furthermore, the severity of sarcopenia is not correlated to the severity of liver fibrosis.

|||||||||| testosterone prodrug (LPCN 1148) / Lipocine
A multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating LPCN 1148 (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_473;
There are trends within this sarcopenic, decompensated cirrhotic population indicating dysfunction in other key physiologic areas, including hematologic, thrombotic, androgenic, metabolic, immunity, and frailty. Potentially related to the failing liver and reduced muscular mass, systemic ammonia levels are high in the majority of the study population which predisposes participants to episodes of overt HE.

|||||||||| Liver nutrition clinic improves nutritional outcomes in patients with advanced cirrhosis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_462;
Geographic spread and pandemic restrictions affected the ability to complete frailty assessment. This dedicated dietetic service for patients with cirrhosis complications improved dietary intake and nutritional status.

|||||||||| Comparison of prognostic value of sarcopenia and MELD score in assessing 28 days and 3 months mortality in patients with cirrhosis of liver (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_456;
Interestingly, sarcopenia was seen to be more in patients with NAFLD than those with ethanol use related cirrhosis of liver Figure: MELD score Mean hand grip strength (Male) Mean transverse psoas muscle thickness (Males) Mean hand grip strength (female) Mean transverse psoas muscle thickness (females) Number of patients died Percentage ? 15 15.97 kg 7.4 mm/m 11.8 kg 5.7 mm/m 11 (52) 21% 16-25 19.9 kg 8.4mm/m 13.6 kg 6.9 mm/m 7 (38) 18% ?26 16.2 kg 8.1 mm/m 13.4 kg 6.3 mm/m 6 (18) 33%

|||||||||| The prevalence and prognostic impact of myosteatosis with and without sarcopenia and its association with age and severity of liver cirrhosis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_452;
MS is present in all but 3 patients with sarcopenia. Furthermore, sarcopenic patients with low SMI are older and have more advanced liver disease compared to sarcopenic with MS but normal SMI, implying that MS predates the decline of muscle strength and performance.

|||||||||| Effects of nutritional therapy on Sarcopenia in patient with liver cirrhosis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_451;
Nutritional therapy is effective in the improvement of sarcopenia and liver function in cirrhosis. Figure: Nil

|||||||||| Correlation between mid-arm circumference and QRS alterations as markers of sarcopenia in patients with decompensated cirrhosis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_448;
The accessibility of these parameters makes them easy to use in clinical practice. Figure: Table.

|||||||||| Nutritional therapy improves minimal hepatic encephalopathy in cirrhosis by improvement in sarcopenia, proinflammatory cytokines and myostatin: a double blind randomized controlled trial (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_447;
Figure: Table. Nutritional therapy is effective in treatment of MHE and associated with improvement in nutritional status, HRQOL, ammonia, endotoxins, inflammatory markers and myostatin levels.

|||||||||| Validation of thigh ultrasound for measurement of sarcopenia and fat mass in patient with cirrhosis: correlation with body composition analysis. Higher fat mass, lower muscle mass and reduced functional muscle (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_417;
Furthermore, lower TMT is associated with increased frailty and reduced muscle function in cirrhosis. Further prospective studies are required to determine if this can be used with other biomarkers to identify patients who would benefit from intensive nutrition intervention.

|||||||||| Nutritional status of patients with advanced chronic liver disease: descriptive baseline of a prospective study (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_409;
RFH-NPT overestimates the risk of malnutrition in decompensated patients, compared to SGA and MUST, which are comparable. There are no differences in the distribution of malnutrition according to Child-Pugh.

|||||||||| Observational data, Journal: Dental care and oral conditions are associated with the prevalence of sarcopenia in people with type 2 diabetes: a cross-sectional study. (Pubmed Central) - Apr 12, 2023
There are no differences in the distribution of malnutrition according to Child-Pugh. This study revealed that dental care and oral conditions were associated with the prevalence of sarcopenia.

|||||||||| Journal: Three-dimensional chromatin re-organization during muscle stem cell aging. (Pubmed Central) - Apr 12, 2023
We observed that muscle stem cells display static behavior at global scales of chromatin organization during aging and extensive rewiring of local contacts at finer scales that were associated with variations in transcription factor binding and aberrant gene expression. These data provide insights into genome topology as a regulator of molecular function in stem cell aging.

|||||||||| Observational data, Retrospective data, Journal: Sarcopenia index based on serum creatinine and cystatin C is associated with mortality in middle-aged and older adults in Chinese: A retrospective cohort study from the China Health and Retirement Longitudinal Study. (Pubmed Central) - Apr 12, 2023
Similarly, as SI was used as a categorical variable according to quartiles, higher SI was associated with lower mortality [Hazard Ratio (HR) = 0.44, 95% CI 0.34-0.57, P < 0.001] after adjustment for confounders. Lower sarcopenia index was associated with higher mortality among middle-aged and older adults in China.

|||||||||| Journal: The Relationship Between Sarcopenia, Cognitive Impairment, and Cerebral White Matter Hyperintensity in the Elderly. (Pubmed Central) - Apr 12, 2023
Lower sarcopenia-related indices were significantly associated with cognitive impairment. WMHs may be one of the factors linking sarcopenia and cognitive function.

|||||||||| New trial: the Effect of Exercise and Oral Supplement Intervention in Sarcopenia Markers in Hemodialysis Patients (clinicaltrials.gov) - Apr 12, 2023
P=N/A, N=200, Not yet recruiting, Sponsor: China Medical University Hospital

|||||||||| New trial: Vold: The Effect of a 12-week Self-composed Vegan Diet With or Without Concurrent Resistance Exercise on Thigh Muscle Volume in Older Adults (clinicaltrials.gov) - Apr 12, 2023
P=N/A, N=72, Not yet recruiting, Sponsor: Wageningen University

|||||||||| New trial: Impact of Postprandial 'Exercise Snacks' on Protein and Glucose Metabolism Following a Period of Step Reduction in Older Adults (clinicaltrials.gov) - Apr 12, 2023
P=N/A, N=20, Recruiting, Sponsor: University of Toronto

|||||||||| Enrollment open, Trial initiation date: Impact of Diet on the Gut-Muscle Axis in Older Adults (clinicaltrials.gov) - Apr 12, 2023
P=N/A, N=24, Recruiting, Sponsor: Tufts University
WMHs may be one of the factors linking sarcopenia and cognitive function. Not yet recruiting --> Recruiting | Initiation date: Sep 2022 --> Mar 2023

|||||||||| The ESCRT protein CHMP5 controls skeletal muscle homeostasis and coordinates myeloid cell-mediated tissue repair (P535) (Exhibit Hall; Poster Board No. P535) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_947;
12 days post-injury, histologic and flow cytometric analyses of muscles from CHMP5het mice revealed less regenerative progress than littermate controls. These data suggest a critical function for CHMP5 in promoting muscle homeostasis both in the steady state and in the context of injury and inflammation.

|||||||||| Journal: A different outlook to consequences of anemia in older adults. (Pubmed Central) - Apr 11, 2023
Anemia and depression are independent factors for low HGS in women, and anemia and age are independent factors for dependency on instrumental daily activities in older persons. Treating depression and raising Hb to optimal levels may be critical interventions to improve the health and life quality of people aged 65 and over, particularly in the female gender.

|||||||||| Clinical: Frequency of Sarcopenia, Sarcopenic Obesity, and Changes in Physical Function in Surgical Oncology Patients Referre… https://t.co/1AQWToiwQ0 (Twitter) - Apr 11, 2023

|||||||||| Clinical, Clinical data, CAR T-Cell Therapy: The cancer dietary literature has got me confused. When diagnosed eat lots of plants but once you need a CART get fat per the data. Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell https://t.co/pbPbGFYDzB (Twitter) - Apr 11, 2023

|||||||||| Retrospective data, Review, Journal: Sarcopenia effect on mortality and spinal cord ischemia after complex aortic aneurysm repair A systematic review and meta-analysis. (Pubmed Central) - Apr 11, 2023
Early mortality does not appear to be affected by sarcopenia in patients treated for thoraco-abdominal aneurysms. However, sarcopenia may be associated with higher peri-operative SCI and midterm mortality rates.

|||||||||| Journal: Acupunch Exercise Improved Muscle Mass, Hand Grip Strength, and Sleep Quality of Institutional Older Adults with Probable Sarcopenia. (Pubmed Central) - Apr 11, 2023
After the 6-month VA exercise intervention, the experimental group showed significant increases in muscle mass (F = 5.93, p = .017), hand grip strength (F = 56.73, p < .001), and improved sleep quality (F = 23.20, p < .001) compared to the control group. Based on the meridian theory that promotes qi and blood circulation, VA exercise has positive effects on muscle mass, hand grip strength, and sleep quality in older adults with probable sarcopenia.

|||||||||| Review, Journal: Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis: Sarcopenia and Nonalcoholic Fatty Liver Disease. (Pubmed Central) - Apr 11, 2023
Low skeletal mass and NAFLD are inversely related; the mechanism is through decreased insulin signaling and insulin resistance, critical for metabolic homeostasis. Weight loss, exercise, and increased protein intake have been effective in reducing NAFLD and sarcopenia.



	Diseases Companies Products Productz Mechanisms of Action Sites